Evaluation of Topical Mitomycin C as Adjuvant Drug to Esophageal Dilation in Children
NCT ID: NCT00551824
Last Updated: 2008-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
10 participants
INTERVENTIONAL
2007-10-31
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a crossover, controlled, clinical trial in which children with esophageal stricture will be randomized in two groups to receive either topical mitomycin or no additional treatment during standard esophageal dilation session.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aims to evaluate mitomycin C as an adjunct to endoscopic treatment of esophageal strictures.
This is a crossover placebo-controlled single-blind clinical trial.
Patients: Subjects up to 18 year-old, with esophageal stricture requiring endoscopic dilation, either due to dysphagia or by stricture preventing passage of the endoscope.
Inclusion criteria:
* peptic esophageal stricture
* post-surgical esophageal stricture
* caustic esophageal stricture
The patient will be randomized by one treatment group, either A or B.
* A. during the first endoscopic procedure it will be applied of topical mitomycin C over the esophageal mucosa after dilation, then the second procedure (in two weeks) will be performed as a standard dilation, without mitomycin C.
* B. the first procedure will be performed in a standard way, and after two weeks, in the second procedure mytomicin-C will be spread over the esophageal mucosa.
The allocation will not be informed to the patient. At the end of the study protocol, the patients will be clinically evaluated and the dilation program will continue on discretion of the assistant doctor. The target esophageal bore is 11 mm (or 12.8 mm if age above 5 yrs).
Mitomycin C will be applied over the esophageal mucosa in the site of stricture after dilation with a cotton pledget soaked in solution (0.4mg/ml) by three minutes. The pledget will he held over the mucosa with a biopsy forceps.
Clinical evaluation. Dysphagia will be evaluated by a structured questionnaire, using a Likert scale. The patient will answer the questionnaire daily.
Main outcome measure: Number of days with improved symptom (dysphagia) after a session.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
First dilation session with topical mitomycin applied over esophageal mucosa after dilation.
Second dilation session (after 14 days): standard dilation without topical mitomycin.
Mitomycin C
Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
2
First dilation session: standard dilation without topical mitomycin.
Second dilation session (after 14 days) with topical mitomycin applied over esophageal mucosa after dilation.
Mitomycin C
Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mitomycin C
Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* and dysphagia
* or stricture preventing endoscope to pass over it.
Exclusion Criteria
* stricture associated to eosinophilic esophagitis
6 Months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federal University of São Paulo
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodrigo S Machado, PhD
Role: PRINCIPAL_INVESTIGATOR
Disciplina de Gastroenterologia Pediátrica, UNIFESP/EPM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital São Paulo
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marcelo Gancz, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MITOMYCIN
Identifier Type: -
Identifier Source: org_study_id